Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689907 · ClinicalTrials.gov registry record
Early Chimerism Following Allogeneic Stem-Cell Transplant
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 40
- Enrollment target
NCT03689907 is a clinical trial that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT03689907 has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood cancers. To determine how many cells are from the donor after transplant, doctors complete a "chimerism analysis" or a test of participant cells to look at the DNA. Chimerism testing helps doctors predict graft rejection or recurrence of disease. Doctors at NCCC do chimerism testing routinely and it is usually done between 30 and 100 days after transplantation. The researchers believe that analyzing chimerism sooner than 30 days after transplant may help identify problems earlier, get patients treatment sooner, and increase the chances of a successful transplant. The purpose of this study is to find out if doing chimerism testing earlier than the traditional approach is better for patient outcomes (about 14 days after transplantation rather than 30+ days). Information gained from this study can be used to help prevent some post-transplant complications such as graft loss, graft-versus-host disease, or even relapse for future patients. Also, the researchers hope to learn more about chimerism testing of cells of patients with haploidentical donors (donors who are only a "half-match" - such as a parent or child of the recipient), because there have not been many chimerism analysis studies done in this population.
Interventions
- OTHER Chimerism Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2024-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03689907
The ClinicalTrials.gov registry entry for NCT03689907 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chimerism Evaluation is the first listed.
NCT03689907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03689907 about?
NCT03689907 is a clinical study titled "Early Chimerism Following Allogeneic Stem-Cell Transplant". Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood cancers. To determine how many cells are from the donor after transplant, doctors complete a "chimerism analysis" or a test of participant cells to look at the DNA. Chimerism testing helps doctors predict graft rej...
What is the current status of trial NCT03689907?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2019-12-19. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT03689907?
The interventions under investigation include: Chimerism Evaluation (OTHER).
Who is sponsoring clinical trial NCT03689907?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.